These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32771950)

  • 1. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.
    Chung IY; Lee JW; Moon HG; Shin KH; Han W; Son BH; Ahn SH; Noh DY
    Breast; 2020 Oct; 53():125-129. PubMed ID: 32771950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group.
    Lee J; Hur H; Lee JW; Youn HJ; Han K; Kim NW; Jung SY; Kim Z; Kim KS; Lee MH; Han SH; Jung SH; Chung IY
    Cancer; 2020 Jan; 126(1):181-188. PubMed ID: 31454422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
    Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010.
    Larsen CM; Garcia Arango M; Dasari H; Arciniegas Calle M; Adjei E; Rico Mesa J; Scott CG; Thompson CA; Cerhan JR; Haddad TC; Goetz MP; Herrmann J; Villarraga HR
    JAMA Netw Open; 2023 Feb; 6(2):e2254669. PubMed ID: 36735254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
    Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
    J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database.
    Choi JY; Cho EY; Choi YJ; Lee JH; Jung SP; Cho KR; Kim CY; Kim YH; Park KH
    Breast Cancer Res Treat; 2018 Aug; 171(1):181-188. PubMed ID: 29737474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer.
    Cespedes Feliciano EM; Chen WY; Lee V; Albers KB; Prado CM; Alexeeff S; Xiao J; Shachar SS; Caan BJ
    JAMA Oncol; 2020 Feb; 6(2):264-270. PubMed ID: 31804676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
    Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
    Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.
    Thavendiranathan P; Abdel-Qadir H; Fischer HD; Camacho X; Amir E; Austin PC; Lee DS
    J Clin Oncol; 2016 Jul; 34(19):2239-46. PubMed ID: 27091709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors.
    Vo JB; Ramin C; Veiga LHS; Brandt C; Curtis RE; Bodelon C; Barac A; Roger VL; Feigelson HS; Buist DSM; Bowles EJA; Gierach GL; Berrington de González A
    J Natl Cancer Inst; 2024 Aug; 116(8):1384-1394. PubMed ID: 38718210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.
    Boekel NB; Schaapveld M; Gietema JA; Russell NS; Poortmans P; Theuws JC; Schinagl DA; Rietveld DH; Versteegh MI; Visser O; Rutgers EJ; Aleman BM; van Leeuwen FE
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1061-72. PubMed ID: 27026313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
    Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
    Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
    Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Rosenstock AS; Niu J; Giordano SH; Zhao H; Wolff AC; Chavez-MacGregor M
    Cancer; 2018 Mar; 124(5):899-906. PubMed ID: 29236294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer.
    Blanco JG; Leisenring WM; Gonzalez-Covarrubias VM; Kawashima TI; Davies SM; Relling MV; Robison LL; Sklar CA; Stovall M; Bhatia S
    Cancer; 2008 Jun; 112(12):2789-95. PubMed ID: 18457324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy.
    Li M; Ma F; Wang J; Li Q; Zhang P; Yuan P; Luo Y; Cai R; Fan Y; Chen S; Li Q; Xu B
    Chin J Cancer; 2018 Jan; 37(1):4. PubMed ID: 29382381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis.
    Feng QJ; Zhang F; Huang XY; Wu ZX
    Pathol Oncol Res; 2014 Jan; 20(1):179-84. PubMed ID: 23980023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines.
    van Dalen EC; van der Pal HJ; van den Bos C; Kok WE; Caron HN; Kremer LC
    Eur J Cancer; 2006 Oct; 42(15):2549-53. PubMed ID: 16919450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
    Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.